Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kips Bay Liquidates As Its Bypass Graft Device Shows Poorly In Study

This article was originally published in The Gray Sheet

Executive Summary

The struggling Minnesota company made a last-ditch effort to complete the eMESH 1 trial of the eSVS Mesh device for coronary artery bypass graft surgery, but the firm, founded by device sector luminary Manny Villafana, has decided to give it up after the early results from the trial proved disappointing.

You may also be interested in...



Kips Bay Fires Staff, Cuts Costs To Keep eSVS Mesh In The Game

The company is downsizing to keep its clinical trial for its eSVS Mesh product on track. It estimates it currently has enough funds to last it through the year, but cautions it may take months to gather patient follow-up data.

COVID-19 Lockdown: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Topics

Related Companies

UsernamePublicRestriction

Register

MT034019

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel